GlaxoSmithKline (NYSE: GSK ) is one of the globe's largest drug companies. The company generates more than $40 billion in annual sales and, given that its dividend yield is nearly 5%, its shares are often included in dividend investor's portfolios.
Glaxo has a solid track record of dividend increases during the past five years; however, investors are right to wonder whether sliding sales tied to patent expiration may put Glaxo's streak in jeopardy.
In the following slideshow, you'll learn whether I think Glaxo's dividend is safe, and see how Glaxo's dividend matches up to its new consumer goods joint venture partner Novartis (NYSE: NVS ) and its competitor AstraZeneca (NYSE: AZN ) .
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.